跳至主要内容
临床试验/JPRN-jRCT1031180386
JPRN-jRCT1031180386进行中(未招募)未知

Comparison of Dapagliflozin and vitamin E Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, Open-Label Controlled Trial

Ikejima Kenichi0 个研究点目标入组 40 人开始时间: 2019年3月20日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 80age old(—)
性别
All

入选标准

  • HbA1c>=6.5% after dietary exercise during pre-observation period (8 to 16 weeks), hepatic steatosis in abdominal US

排除标准

  • 1.ethanol consumption over 30g/d in Male or 20g/d in Female
  • 2.type 1 diabetic patients
  • 3. poor glycemic control HbA1c>=8.4%
  • 4.patients who are being treated for liver disease other than NAFLD
  • 5.Male: serum creatinine higher than 1.2mg/dL Female: serum creatinine higher than 1.0mg/dL patients
  • 6.Patients who cannot be aware of dry mouth
  • 7.SGLT2 inhibitor contraindication case
  • 8.Patients with a history of hypersensitivity to SGLT2 inhibitor/Vit. E
  • 9.Patients judged to be ineligible by a doctor

研究者

发起方
Ikejima Kenichi

相似试验